Back to Agenda
Unlocking the Potential of Pharmacogenomics for Reducing the Burden of Adverse Drug Reactions
Session Chair(s)
Alison Cave, PhD
Chief Safety Officer
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
This session will explore current progress in pharmacogenomics; the barriers and opportunities it represents for drug safety from the perspective of medicines regulators, industry, the scientific community, healthcare professionals, and patients.
Learning Objective : Discuss the importance of pharmacogenomics for introducing better risk mitigation strategies; Appraise progress being made in this field internationally; Recognize opportunities for introduction of pharmacogenomic research in your organization.
Speaker(s)
From Post-Marketing Reports of Side Effects to Pharmacogenomic Research: Can we Reduce the Burden of ADRs?
Alison Cave, PhD
Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom
Chief Safety Officer
Patient Perspective
Christine Von Raesfeld
The Light Collective, United States
Founder/SME, Patient Experience
Industry Perspective
Gregory Powell, PharmD, MBA
GlaxoSmithKline, United States
Senior Director, Safety and Clinical Innovation
Academic Perspective
Kathleen M. Giacomini, PhD
University of California San Francisco, United States
Dean, School of Pharmacy, Professor and Principal Investigator
Have an account?